PARK HA BIOLOGICAL TECH-A
BYAHNASDAQTrading Snapshot
- Day Range
- $2.37 – $2.40
- 52-Week Range
- $2.04 – $215.60
- Volume
- $1.51B
- Avg Volume
- $1.81B
- Shares Outstanding
- 747,902
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $1M
- P/E Ratio
- -0.0
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-13.27
- Dividend Yield
- 0.00%
Why Investors Own BYAH
- ✓High-growth profile — revenue up -3.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PARK HA BIOLOGICAL TECH-A
BYAH
StockOtter · stockotter.spaceAbout PARK HA BIOLOGICAL TECH-A
This enterprise functions as an investment holding company, with its core business centered on crafting and distributing skincare solutions. Operating under the "Park Ha" brand, these products are sold across the People's Republic of China. The company executes these activities through its affiliated subsidiaries, which manage both direct product sales and the provision of franchise services.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Bronstein, Gewirtz & Grossman LLC Urges Park Ha Biological Technology Co., Ltd. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Park Ha Biological Technolog
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Park Ha Biological Technology Co., Ltd. Lawsuit - BYAH
BYAH allegedly structured its IPO with a public float of just 1,200,000 shares, representing less than 5% of the company, a structure the lawsuit contends enabled coordinated price manipulation before BYAH shares collaps
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Park Ha Biological Technology Co., Ltd. of Class Action Lawsuit and Upcoming Deadlines - BYAH
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd.
PHH, BYAH Deadline: Rosen Law Firm Urges Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ:
PHH, BYAH DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Park Ha Biological Technology Co., Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 28 Deadline in Securities Class Action - PHH, BYAH
New York, New York--(Newsfile Corp. - September 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH) (NASDAQ: BYAH)
SueWallSt Reminds Park Ha Biological Technology Co. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - BYAH
BYAH CFO Xiaoyan Zhu since 2016 signed the December 2024 registration statement that the lawsuit contends omitted the promotional scheme behind BYAH's 93% stock collapse. NEW YORK, Sept.